Home Stock

Stock Research: SCI Pharmtech

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

SCI Pharmtech

TAI:4119 TW0004119003
27
  • Value
    14
  • Growth
    66
  • Safety
    Safety
    63
  • Combined
    42
  • Sentiment
    24
  • 360° View
    360° View
    27
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

SCI Pharmtech, Inc. is a Taiwan-based company focused on manufacturing and selling Active Pharmaceutical Ingredients (APIs). The company operates in the pharmaceutical industry, producing APIs, API intermediates, and special chemicals. It distributes its products in Taiwan, Europe, the Americas, and other parts of Asia. In the last fiscal year, the company had a market cap of $254 million, profits of $13 million, and revenue of $46 million. The number of employees is not available.

more

ANALYSIS: With an Obermatt 360° View of 27 (better than 27% compared with alternatives), overall professional sentiment and financial characteristics for the stock SCI Pharmtech are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for SCI Pharmtech. The consolidated Growth Rank has a good rank of 66, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 66% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 63 which means that the company has a financing structure that is safer than 63% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 14 which means that the share price of SCI Pharmtech is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 86% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 24, which means that professional investors are more pessimistic about the stock than for 76% of alternative investment opportunities. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Liquidity
Country Taiwan
Industry Pharmaceuticals
Size Small
Website sci-pharmtech.com.tw
Index
SCI Pharmtech stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 30-Jul-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
14 22 16 35
Growth
66 74 97 83
Safety
Safety
63 27 51 88
Sentiment
24 8 20 37
360° View
360° View
27 7 36 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
14 12 25 28
Opinions Change
50 50 50 50
Pro Holdings
n/a 32 38 55
Market Pulse
39 1 1 n/a
Sentiment
24 8 20 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
14 22 16 35
Growth
66 74 97 83
Safety Safety
63 27 51 88
Combined
42 27 56 86
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
18 18 9 20
Price vs. Earnings (P/E)
18 14 42 20
Price vs. Book (P/B)
55 31 29 48
Dividend Yield
1 44 21 75
Value
14 22 16 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
62 94 49 83
Profit Growth
30 70 100 23
Capital Growth
58 18 95 84
Stock Returns
61 56 71 65
Growth
66 74 97 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
61 41 55 96
Refinancing
35 24 21 35
Liquidity
75 49 78 100
Safety Safety
63 27 51 88

Similar Stocks

Discover high‑ranked alternatives to SCI Pharmtech and broaden your portfolio horizons.

CK Asset Holdings

HKG:1113
Country: Hong Kong
Industry: Real Estate Development
Size: X-Large
Full Stock Analysis

Kinden

TYO:1944
Country: Japan
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

Phison Electronics

TWO:8299
Country: Taiwan
Industry: Semiconductors
Size: Medium
Full Stock Analysis

Tripod Technology

TAI:3044
Country: Taiwan
Industry: Electronic Components
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews